Sucampo Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St futures gain as chip stocks extend recovery; earnings in focus
- Oil prices firm as investors weigh fresh attacks against potential US-Iran ceasefire
- Chip stocks extend global rebound following last week's rout
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- Danaher shares tumble despite earnings beat
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Jefferies Raises Price Target on Sucampo Pharma (SCMP) Following 3Q Report
November 10, 2016 10:10 AM ESTJefferies reiterated a Hold rating on Sucampo Pharmaceuticals (NASDAQ: SCMP), and raised the price target to $16.00 (from $14.00), following the company's 3Q earnings report. SCMP reported 3Q EPS of $0.28, compared to Jefferies' $0.25 estimate. Revenues of $58M, +$7M ahead of estimates. Based on the Q3... More
Sucampo Pharma (SCMP) Tops Q3 EPS by 2c, Guidance Beats
November 9, 2016 8:38 AM ESTSucampo Pharma (NASDAQ: SCMP) reported Q3 EPS of $0.28, $0.02 better than the analyst estimate of $0.26. Revenue for the quarter came in at $57.9 million versus the consensus estimate of $51.46 million.
GUIDANCE:
Sucampo Pharma sees FY2016 EPS of $1.20-$1.25, versus the consensus of... More
